Browsing by Author "Paripovic, Lejla (55342754900)"
Now showing 1 - 10 of 10
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Assessment of health-related quality of life among parents of children with solid tumors in Serbia(2020) ;Ilic, Vesna (58717187600) ;Nikitovic, Marina (6602665617) ;Maric, Gorica (56433592800) ;Jovanovic, Aleksa (57216047949) ;Paripovic, Lejla (55342754900) ;Bokun, Jelena (6507641875) ;Stanic, Dragana (56941616400) ;Vukovic, Marija Popovic (57203171901) ;Tepavcevic, Darija Kisic (57218390033)Pekmezovic, Tatjana (7003989932)Purpose: The aim of the study was to assess health-related quality of life (HRQoL) and contributing factors among parents of children with solid tumors in Serbia. Methods: The cross-sectional study included 51 parents of children treated for different solid tumors at the Institute of Oncology and Radiology of Serbia. Parents filled out validated Serbian version of SF-36 questionnaire. Hierarchical multiple regression analysis was conducted to identify predictors of total score of SF-36. Results: Almost all parents (94.1%) were mothers and average age was 38.6 ± 6.7 years. Majority of children had brain tumors (43.1%), followed by bone tumors (37.3%). The hierarchical regression analysis showed that socio-demographic characteristics explained 26% of the variance (p > 0.05) of the total score of SF-36. Addition of quality of life of children assessed by parents in the second model caused an increase of 21% in the variance explained (p < 0.05). After adding the Beck Depression Inventory score in the third block, an additional 18% of the variance in total score was explained (p < 0.05). Conclusions: This study showed that HRQoL measured by SF-36 in parents of children with cancer is strongly influenced by depression and quality of life of children assessed by parents. © 2020, Springer-Verlag GmbH Germany, part of Springer Nature. - Some of the metrics are blocked by yourconsent settings
Publication Colon carcinoma in a child treated with oxaliplatin and antiangiogenic treatment regimens(2012) ;Krstovski, Nada (24724852600) ;Dokmanovic, Lidija (15729287100) ;Lazic, Jelena (7004184322) ;Rodic, Predrag (15846736800) ;Paripovic, Lejla (55342754900)Janic, Dragana (15729368500)Colorectal carcinoma is an extremely rare tumor in childhood. Therefore, the role of adjuvant chemotherapy has not been adequately evaluated in children leading to limited data on safety profile and treatment response after application of novel drugs and novel targeted agents. In this report, we describe a case of colon adenocarcinoma in a 13-year-old girl treated with standard adult treatment as well as novel targeted therapy. This case report illustrates initial good disease control with FOLFOX therapy. On the other hand, targeted therapy revealed no improvement in disease control and good safety profile without significant adverse effects. © 2012 Informa Healthcare USA, Inc. - Some of the metrics are blocked by yourconsent settings
Publication Evaluation of predictive value of 1H MR spectroscopy for response of neoadjuvant chemotherapy in musculoskeletal tumors(2018) ;Cirkovic, Predrag (57204901452) ;Mihailovic, Jelena (57221351293) ;Paripovic, Lejla (55342754900) ;Ilic, Vesna (58717187600) ;Ristic, Dusan (8869432800) ;Djurisic, Igor (13411475700) ;Djordjevic, Aleksandar (57204893297)Maksimovic, Ruzica (55921156500)Purpose: Bone and soft tissue tumors are rare. There is a variety of types and each one has its own particular behavior, treatment and patient outcome. The assessment of treatment response following the 3rd cycle of chemotherapy is one of the most important aspects of patient care, as therapeutic options and the timing of surgery may vary depending on the achievement of response. Hence, we focused on the advanced imaging technique, proton magnetic resonance spectroscopy (1H MRS), aiming at improving the diagnostic accuracy and the tumor response to therapy, based on the absolute concentration of choline (Cho) as biomarker of malignancy. Methods: Twenty patients were studied. All of them had a pathological diagnosis after biopsy. MRI examinations were performed using a 1.5 T MR scanner (Avanto; Siemens, Erlangen, Germany). Single-voxel 1H MR spectroscopy was performed by using a PRESS with TR/TE 1530/100 ms, before chemotherapy and after the 3rd cycle. 1H MRS was processed in LC model. Results: Of 20 patients, 7 responded to neoadjuvant chemotherapy and 13 did not. In responders, the mean concentration of tCho before therapy was 4.7±2.5 mmol/kg, which showed statistically significant reduction after therapy. In non-responders, the mean tCho concentration before therapy was 2.9±0.9 mmol/kg which remained the same or increased after the 3rd cycle of neoadjuvant chemotherapy (2.7±2.5 mmol/kg; range from 2.05 to 5.79 with no statistical significance). Compared to reference healthy group, tCho concentrations were increased in all cases. Conclusions: 1H MRS appears to be valuable technique for evaluation of response to neoadjuvant chemotherapy of patients with musculoskeletal tumors (MSK). © 2018 Zerbinis Publications. All Rights Reserved. - Some of the metrics are blocked by yourconsent settings
Publication Evaluation of predictive value of 1H MR spectroscopy for response of neoadjuvant chemotherapy in musculoskeletal tumors(2018) ;Cirkovic, Predrag (57204901452) ;Mihailovic, Jelena (57221351293) ;Paripovic, Lejla (55342754900) ;Ilic, Vesna (58717187600) ;Ristic, Dusan (8869432800) ;Djurisic, Igor (13411475700) ;Djordjevic, Aleksandar (57204893297)Maksimovic, Ruzica (55921156500)Purpose: Bone and soft tissue tumors are rare. There is a variety of types and each one has its own particular behavior, treatment and patient outcome. The assessment of treatment response following the 3rd cycle of chemotherapy is one of the most important aspects of patient care, as therapeutic options and the timing of surgery may vary depending on the achievement of response. Hence, we focused on the advanced imaging technique, proton magnetic resonance spectroscopy (1H MRS), aiming at improving the diagnostic accuracy and the tumor response to therapy, based on the absolute concentration of choline (Cho) as biomarker of malignancy. Methods: Twenty patients were studied. All of them had a pathological diagnosis after biopsy. MRI examinations were performed using a 1.5 T MR scanner (Avanto; Siemens, Erlangen, Germany). Single-voxel 1H MR spectroscopy was performed by using a PRESS with TR/TE 1530/100 ms, before chemotherapy and after the 3rd cycle. 1H MRS was processed in LC model. Results: Of 20 patients, 7 responded to neoadjuvant chemotherapy and 13 did not. In responders, the mean concentration of tCho before therapy was 4.7±2.5 mmol/kg, which showed statistically significant reduction after therapy. In non-responders, the mean tCho concentration before therapy was 2.9±0.9 mmol/kg which remained the same or increased after the 3rd cycle of neoadjuvant chemotherapy (2.7±2.5 mmol/kg; range from 2.05 to 5.79 with no statistical significance). Compared to reference healthy group, tCho concentrations were increased in all cases. Conclusions: 1H MRS appears to be valuable technique for evaluation of response to neoadjuvant chemotherapy of patients with musculoskeletal tumors (MSK). © 2018 Zerbinis Publications. All Rights Reserved. - Some of the metrics are blocked by yourconsent settings
Publication Management and treatment of children with medulloblastoma in Serbia, a middle-income country(2018) ;Bokun, Jelena (6507641875) ;Grujicic, Danica (7004438060) ;Skender-Gazibara, Milica (22836997600) ;Paripovic, Lejla (55342754900) ;Pekmezovic, Tatjana (7003989932) ;Kisic-Tepavcevic, Darija (57218390033) ;Ilic, Vesna (58717187600) ;Raicevic, Savo (56176851100) ;Stanic, Dragana (56941616400) ;Miskovic, Ivana (57126111500) ;Saric, Milan (19738345400)Nikitovic, Marina (6602665617)Purpose: The aim of this study was to present the management and treatment of children with medulloblastoma in Serbia, a middle-income country (MIC). Methods: The data of 87 children diagnosed with medulloblastoma and treated at the Institute for Oncology and Radiology of Serbia from 2000 to 2013 were analyzed. Results: The children’s median age was 8.3 years (range 2.5-17.3). Eighty-two (94.2%) were 3 years or older. Sixty-two (71.3%) patients had stage M0 medulloblastoma, 12 (13.8%) had stage M1 and 13 (14.9%) had stage M2 or M3. As of October 2015, 51 (58.6%) patients were alive and 31 (35.6%) had died. Five patients (5.7%) were lost to followup. Twenty-six patients relapsed. The median follow-up time was 58 months (range 4–187). Mean overall survival (OS) was 76.4% at 3 years, 66.2% at 5 years and 59.2% at 10 years. Mean disease-free survival (DFS) was 75.8% at 3 years, 62.8% at 5 years and 56.6% at 10 years. Mean OS of stage M0 patients was 86.4% at 3 years, 74% at 5 years and 63.1% at 10 years. The OS of stage M1, M2 and M3 patients combined was 48.9% at 3 years, 44.0% at 5 years and 37.7% at 10 years. Conclusion: In Serbia, a MIC, it is possible to achieve good treatment results in children with medulloblastoma using international treatment guidelines and recommendations, available resources and an experienced team of professionals dedicated to pediatric neurooncology. © 2018 Zerbinis Publications. All Rights Reserved. - Some of the metrics are blocked by yourconsent settings
Publication Management and treatment of children with medulloblastoma in Serbia, a middle-income country(2018) ;Bokun, Jelena (6507641875) ;Grujicic, Danica (7004438060) ;Skender-Gazibara, Milica (22836997600) ;Paripovic, Lejla (55342754900) ;Pekmezovic, Tatjana (7003989932) ;Kisic-Tepavcevic, Darija (57218390033) ;Ilic, Vesna (58717187600) ;Raicevic, Savo (56176851100) ;Stanic, Dragana (56941616400) ;Miskovic, Ivana (57126111500) ;Saric, Milan (19738345400)Nikitovic, Marina (6602665617)Purpose: The aim of this study was to present the management and treatment of children with medulloblastoma in Serbia, a middle-income country (MIC). Methods: The data of 87 children diagnosed with medulloblastoma and treated at the Institute for Oncology and Radiology of Serbia from 2000 to 2013 were analyzed. Results: The children’s median age was 8.3 years (range 2.5-17.3). Eighty-two (94.2%) were 3 years or older. Sixty-two (71.3%) patients had stage M0 medulloblastoma, 12 (13.8%) had stage M1 and 13 (14.9%) had stage M2 or M3. As of October 2015, 51 (58.6%) patients were alive and 31 (35.6%) had died. Five patients (5.7%) were lost to followup. Twenty-six patients relapsed. The median follow-up time was 58 months (range 4–187). Mean overall survival (OS) was 76.4% at 3 years, 66.2% at 5 years and 59.2% at 10 years. Mean disease-free survival (DFS) was 75.8% at 3 years, 62.8% at 5 years and 56.6% at 10 years. Mean OS of stage M0 patients was 86.4% at 3 years, 74% at 5 years and 63.1% at 10 years. The OS of stage M1, M2 and M3 patients combined was 48.9% at 3 years, 44.0% at 5 years and 37.7% at 10 years. Conclusion: In Serbia, a MIC, it is possible to achieve good treatment results in children with medulloblastoma using international treatment guidelines and recommendations, available resources and an experienced team of professionals dedicated to pediatric neurooncology. © 2018 Zerbinis Publications. All Rights Reserved. - Some of the metrics are blocked by yourconsent settings
Publication Post-treatment FDG PET/CT predicts progression-free survival in young patients with small round blue cell tumors: Ewing sarcoma and PNET(2020) ;Sobic Saranovic, Dragana P. (57202567582) ;Nikitovic, Marina (6602665617) ;Saponjski, Jelena (57207943674) ;Grozdic Milojevic, Isidora (37107616900) ;Paripovic, Lejla (55342754900) ;Saranovic, Djordjije (57190117313) ;Beatovic, Slobodanka (6507312377)Artiko, Vera M. (55887737000)Purpose: To determine if post-treatment F-18 FDG PET/CT results (overall positive findings, specific localizations) are independent predictors of disease progression in young patients with Ewing sarcoma and Primitive neuroectodermal tumor. Method: A consecutive sample of 48 patients (age 14 ± 5 years, 32 male) was referred to F-18 FDG PET/CT for the suspected progression of Ewing sarcoma (39 patients) and Primitive neuroectodermal tumor (PNET) (9 patients) and followed-up clinically for 4.3 ± 2.3 years after F-18 FDG PET/CT (range 1–8 years). The diagnostic value of F-18 FDG PET/CT was determined in comparison to the biopsy. Kaplan-Meier analysis was used to compare progression-free survival between the groups with positive and negative F-18 FDG PET/CT findings. Variables included in the Cox regression for predicting the progression-free survival were sex, age, F-18 FDG PET/CT findings, MDCT findings, and MR ratio. Results: F-18 FDG PET/CT findings were positive in 32 (67 %) patients (sensitivity 93.7 %, specificity 87.5 %, accuracy 91.7 %) with an average SUVmax of 5.8 ± 3.2 (95 % CI 4.8–7.1). The progression-free survival was significantly lower (p = 0.001) in patients with positive F-18 FDG PET/CT findings (median 28 months) and when recurrence was located in bones, soft tissues, and muscles (p = 0.02, median 21 months). The significant predictors of the disease progression were the overall positive F-18 FDG PET/CT findings (HR 8.36, p = 0.004) and, specifically, the local recurrence in the bone with infiltration of soft tissue/muscles (HR 4.08, p = 0.003). Conclusion: Post-treatment F-18 FDG PET/CT findings are useful for predicting the progression of Ewing sarcoma and PNET and should be included in the clinical monitoring of these patients. © 2020 Elsevier B.V. - Some of the metrics are blocked by yourconsent settings
Publication Treatment outcome of childhood nasopharyngeal carcinoma: A single institution experience(2018) ;Nikitovic, Marina (6602665617) ;Popovic-Vukovic, Marija (57203171901) ;Stanic, Dragana (56941616400) ;Bokun, Jelena (6507641875) ;Paripovic, Lejla (55342754900) ;Ilic, Vesna (58717187600) ;Miskovic, Ivana (57126111500)Saric, Milan (19738345400)Objectives: Nasopharyngeal carcinoma is a rare malignancy in children. The aim of this study was to provide analysis of children with nasopharyngeal carcinoma treated in a single institution. Methods and materials: Between 1999 and 2016, fourteen pediatric patients with a diagnosis of undifferentiated nasopharyngeal carcinoma were treated in our institution, and the patients’ clinical characteristics, treatment modality, outcome, and toxicity were analyzed. Results: The median age at diagnosis was 15,5 years. The gender ratio was 1:1. The majority of patients had regionally and/or locally advanced tumors and one had bone metastases at the time of diagnosis. All patients received chemotherapy before radiotherapy, with partial response in thirteen patients and complete response in one. Radiation dose to the primary tumor and involved cervical lymph nodes was 55–60 Gy, uninvolved cervical and supraclavicular regions received prophylactic radiation with dose of 45–50 Gy. Ten patients received adjuvant chemotherapy. Three-year progression-free rate and three-year overall survival (OS) rates were 75% and 73% respectively. Five-year progression-free rate was 65% and OS 63% respectively, and after ten years progression-free rate and OS remained the same. At the end of follow-up period, ten patients were alive, and four died. All of the patients that had distant metastases died. Most common late complications were skin fibrosis and xerostomia. Conclusions: Multimodal therapy of children with nasopharyngeal carcinoma is associated with long-term survival. It is expected that further advances in the management of these patients, with improved radiotherapy and chemotherapy, will reduce acute and late toxicity and improve quality of life of treated children. © 2018 - Some of the metrics are blocked by yourconsent settings
Publication Treatment results of childhood Ewing’s sarcoma of the bone in Serbia(2018) ;Paripovic, Lejla (55342754900) ;Ilic, Vesna (58717187600) ;Slovic, Marija Pudrlja (57204901186) ;Bokun, Jelena (6507641875) ;Cirkovic, Predrag (57204901452) ;Djordjevic, Aleksandar (57204893297) ;Sopta, Jelena (24328547800) ;Vujic, Dragana (16647611700) ;Saric, Milan (19738345400)Nikitovic, Marina (6602665617)Purpose: The purpose of this study was to present treatment results of childhood Ewing’s sarcoma (ES) of the bone in Serbia and to analyze prognostic factors. Methods: We performed a detailed analysis on a series of 107 patients with ES of the bone treated at the Institute for Oncology and Radiology of Serbia between 2000 and 2014, using modern multimodal therapy. Results: Median age at the time of diagnosis was 14 years, with 56.07% of the patients being =14 years. There was a male predominance (59.81%). The most common primary sites were pelvis (25.23%), femur (17.76%) and tibia (12.15%). Thirty-four patients (31.78%) had metastatic disease, 17 of which had isolated lung metastases, 9 bone metastases and 8 patients had both. Tumor size = 8 cm had 38.32% and >8 cm had 61.68% patients. Overall, 51.4% patients underwent surgery and radiotherapy as a local treatment modality after neoadjuvant chemotherapy. Radiotherapy alone was performed in 24 patients. The 5-year overall survival (OS) was 43.8%. For patients with localized disease, the 5-year OS was 56.4% and for patients with metastatic disease 17.6%. In patients with initially nonmetastatic disease, age under 14 years, with tumor size <8 cm and a good response to the neoadjuvant chemotherapy, the OS correlated with better outcome. Conclusions: Modern multidisciplinary approach in treatment of childhood ES of the bone in accordance with the recommended pediatric protocols, gives good treatment results. Therapy should be performed in referral centers. © 2018 Zerbinis Publications. All Rights Reserved. - Some of the metrics are blocked by yourconsent settings
Publication Treatment results of childhood Ewing’s sarcoma of the bone in Serbia(2018) ;Paripovic, Lejla (55342754900) ;Ilic, Vesna (58717187600) ;Slovic, Marija Pudrlja (57204901186) ;Bokun, Jelena (6507641875) ;Cirkovic, Predrag (57204901452) ;Djordjevic, Aleksandar (57204893297) ;Sopta, Jelena (24328547800) ;Vujic, Dragana (16647611700) ;Saric, Milan (19738345400)Nikitovic, Marina (6602665617)Purpose: The purpose of this study was to present treatment results of childhood Ewing’s sarcoma (ES) of the bone in Serbia and to analyze prognostic factors. Methods: We performed a detailed analysis on a series of 107 patients with ES of the bone treated at the Institute for Oncology and Radiology of Serbia between 2000 and 2014, using modern multimodal therapy. Results: Median age at the time of diagnosis was 14 years, with 56.07% of the patients being =14 years. There was a male predominance (59.81%). The most common primary sites were pelvis (25.23%), femur (17.76%) and tibia (12.15%). Thirty-four patients (31.78%) had metastatic disease, 17 of which had isolated lung metastases, 9 bone metastases and 8 patients had both. Tumor size = 8 cm had 38.32% and >8 cm had 61.68% patients. Overall, 51.4% patients underwent surgery and radiotherapy as a local treatment modality after neoadjuvant chemotherapy. Radiotherapy alone was performed in 24 patients. The 5-year overall survival (OS) was 43.8%. For patients with localized disease, the 5-year OS was 56.4% and for patients with metastatic disease 17.6%. In patients with initially nonmetastatic disease, age under 14 years, with tumor size <8 cm and a good response to the neoadjuvant chemotherapy, the OS correlated with better outcome. Conclusions: Modern multidisciplinary approach in treatment of childhood ES of the bone in accordance with the recommended pediatric protocols, gives good treatment results. Therapy should be performed in referral centers. © 2018 Zerbinis Publications. All Rights Reserved.
